Next Article in Journal
Synaptic Pruning by Microglia in Epilepsy
Next Article in Special Issue
Immunomodulation of Murine Chronic DSS-Induced Colitis by Tuftsin–Phosphorylcholine
Previous Article in Journal
Basis of PD1/PD-L1 Therapies
Previous Article in Special Issue
Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 8
Issue 12
10.3390/jcm8122169
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules

by
Christine Verdon
1,2,
Talat Bessissow
1 and
Peter L. Lakatos
1,3,*
1
Division of Gastroenterology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada
2
Department of Gastroenterology, Campbelltown Hospital, Sydney, NSW 2560, Australia
3
1st Department of Medicine, Semmelweis University, Budapest H1083, Hungary
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(12), 2169; https://doi.org/10.3390/jcm8122169
Submission received: 14 November 2019 / Revised: 2 December 2019 / Accepted: 6 December 2019 / Published: 8 December 2019
(This article belongs to the Special Issue Ulcerative Colitis: Current and Emerging Treatment Strategies)
Versions Notes

Abstract

Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%–30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as well as the availability of new treatment options with the development of new biological and small molecules; however, data is limited regarding their use in the context of ASUC. This review aims to discuss the emerging data regarding biologicals and small molecules therapies in the context of ASUC.
Keywords: acute severe ulcerative colitis; infliximab; cyclosporine; tacrolimus; corticosteroids; surgical management acute severe ulcerative colitis; infliximab; cyclosporine; tacrolimus; corticosteroids; surgical management

Share and Cite

MDPI and ACS Style

Verdon, C.; Bessissow, T.; Lakatos, P.L. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J. Clin. Med. 2019, 8, 2169. https://doi.org/10.3390/jcm8122169

AMA Style

Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. Journal of Clinical Medicine. 2019; 8(12):2169. https://doi.org/10.3390/jcm8122169

Chicago/Turabian Style

Verdon, Christine, Talat Bessissow, and Peter L. Lakatos. 2019. "Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules" Journal of Clinical Medicine 8, no. 12: 2169. https://doi.org/10.3390/jcm8122169

APA Style

Verdon, C., Bessissow, T., & Lakatos, P. L. (2019). Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. Journal of Clinical Medicine, 8(12), 2169. https://doi.org/10.3390/jcm8122169

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop